Phase 1 Myeloma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are generally able to carry out daily activities and care for yourself, with little or no limitation due to your illness (this is measured by a standard scale called ECOG, with a score of 0 or 1)
- You have been diagnosed with multiple myeloma that has come back or stopped responding to your most recent treatment
- Your disease can be detected and measured through specific blood, urine, or other laboratory tests
Who may not be able to join:
- You have previously been treated with a drug called etentamig
- You have previously received any treatment that targets a protein called BCMA (confirm with trial site for specific therapies this includes)
- You have previously been treated with either of two specific drugs called iberdomide or mezigdomide (which belong to a class of drugs known as CELMoDs)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Phone: 844-663-3742
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
5 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Phase 1: Dose-Limiting Toxicities (DLT)s of Etentamig when given in Combination with Iberdomide in Participants with Relapsed/Refractory Multiple Myeloma (RRMM); Number of Participants with Adverse Events (AE)s
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.